Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

BioCardia Earnings Call: Key Takeaways

BioCardia is pivoting toward Japanese regulatory approval for Cardiamp and US de novo approval for Helix, while managing a tight $2.2 million cash runway into 2027.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Mgmt ConfidenceConfident in Japan approval; cautious on US de novo pathway timelines.
Demand VisibilityIdentified 300,000 potential ischemic heart failure patients in Japan.
Margin TrendsR&D expenses decreased to $3.4 million YTD from $3.8 million.
Op. LeverageAnnual burn rate maintained at approximately $6 million while running Phase 3.
Pricing PowerNoted peer therapy reimbursement in Japan at over $300,000 per treatment.
Segment GrowthJapan initial indication targeting 20,000 patients post-approval.
New ClientsFour gene therapy collaboration conversations held in the last 72 hours.
Capex & DebtEnded quarter with $2.2 million cash and cash equivalents.
RegulatoryPMDA submission pending; FDA de novo submission expected Q1 2027.
CommentaryFocusing on autologous cell therapy to align with Japanese cultural preferences.
New LaunchesHelix Transcendental delivery system US launch targeted for mid-2027.

Growth

Net loss decreased to $5.7 million year-to-date from $6.2 million in 2025.

Outlook

Targeting Japan approval mid-2027 for 20,000 initial patients; US Helix approval mid-2027.

Risks

Management evaded specific enrollment numbers for CHF II trial, citing focus on regulatory priorities.

Source

The company's earnings call, NASDAQ: BCDA, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

BioCardia, Inc.: key numbers

Share price
$0.7901Close, Nov 16
Market cap
$12M
Shares outstanding
15.14MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from BioCardia, Inc.

All →
4:12 PM ET 8-K
Financial Results

BioCardia Financial Results

BioCardia reported financial results for the third quarter ended September 30, 2026, and provided updates on its regulatory progress in Japan and the U.S. The company successfully completed pre-submission interactions with Japan's PMDA for its CardiAMP cell therapy and expects to file for FDA De Novo approval of its Helix delivery system in Q1 2027.

“We believe that our CardiAMP autologous cell therapy is on track to be the first approved minimally invasive biologic therapy for the treatment of heart failure in a first world country based on the recent interactions with Japan’s Pharmaceutical and Medical Devices Agency.”

Peter Altman, PhD, Chief Executive Officer of BioCardia

“In addition, in the coming months, we aim to be able to submit our Helix transendocardial delivery platform for FDA approval, which would be the first delivery system of its type approved in the United States. This promises to be an exciting year ahead.”

Peter Altman, PhD, Chief Executive Officer of BioCardia
4:08 PM ET 10-Q
Financial Results ▶ Call

BioCardia Q3 2026 Results: Net Loss of $1.82M, Loss Widens

BioCardia, Inc. reported a net loss of $5.7 million for the nine months ended September 30, 2026, compared to a $6.2 million loss in the prior year period. The company ended the quarter with $2.2 million in cash and cash equivalents, supported by $5.3 million in proceeds from common stock sales during the year.

Key figure
Net loss $1.82M
8:31 AM ET 8-K
Business Update

BioCardia Business Update

BioCardia has completed the clinical consultation process with Japan's PMDA regarding application materials for its CardiAMP Cell Therapy System. This milestone allows the company to advance toward a formal marketing approval application for the treatment of ischemic heart failure in Japan, with initial patient treatments and commercial revenues targeted for 2028.

Counterparty
Pharmaceuticals and Medical Devices Agency (PMDA)
9:15 AM ET 8-K
Business Update

BioCardia Business Update

BioCardia announced that the FDA has accepted its revised De Novo pre-submission package for the marketing clearance of its Helix transendocardial delivery catheter. The company expects a substantive review and a meeting with the FDA to discuss the approval pathway during the current quarter.

9:00 AM ET 8-K
Clinical Trial Data

BioCardia Clinical Trial Data

BioCardia announced it will present the trial design and scientific support for its CardiAMP HF II Study at the Heart Failure Society of America Annual Scientific Meeting. The study evaluates a high-dose autologous cell treatment for patients with ischemic heart failure of reduced ejection fraction (HFrEF) who remain symptomatic despite medical therapy.

Counterparty
Heart Failure Society of America
9:15 AM ET 8-K
Business Update

BioCardia Business Update

BioCardia has submitted a revised Pre-Submission to the FDA Center for Devices and Radiological Health (CDRH) for the approval of its Helix Catheter for therapeutic and diagnostic delivery to the heart. The submission incorporates prior FDA feedback regarding marketing clearance pathways and safety data, with the FDA expected to provide written feedback or hold a meeting within 70 days. An independent clearance would allow BioCardia to partner with other developers of cell, gene, and protein therapeutics requiring targeted cardiac delivery.

Counterparty
FDA

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.